These are the stocks posting the largest moves before the bell.Market Insiderread more
U.S. stock futures pointed to a higher open on Monday as Treasury yields rebounded to quell fears of a possible recession.US Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Amid the headlines of stores closures and retail bankruptcies, it can be tough to accept that the U.S. consumer is doing just fine.Retailread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Dow to jump; Trump defends economy; Huawei hopes for US reprieve; Trump and Apple's Tim Cook meet; president ties Hong Kong protests to China trade disputeMarketsread more
We tested the best way to cut the airport commute time for New Yorkers. The most expensive of the four options we reviewed, Uber Copter, was only 14 minutes faster than mass...Transportationread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Ian Read, the chief executive of Pfizer, has hit back at the suggestion that some of AstraZeneca's important, potentially life-saving drugs may be delayed if Pfizer is successful in its $100 billion plus bid for the company.
Pascal Soriot, chief executive of prey AstraZeneca, suggested in an interview with CNBC Tuesday that potential "disruptions" caused by the takeover may impact the delivery of medicines.
In his second quizzing by U.K. members of parliament (MPs) within two days, Read said that key AstraZeneca medicines would be "ring-fenced" and potentially even brought to market more quickly, if the takeover was successful.
Mikael Dolsten, the company's head of research and development, spoke of creating a "powerhouse of science" through the merger. Combining cancer research would help both companies compete more effectively against other players like Novartis and Roche, Read argued.
Pfizer is facing an unprecedented level of scrutiny in the U.K., even though it has yet to make an offer which has been accepted by AstraZeneca's board. The maker of Viagra has pledged to keep 20 percent of its global research and development in the U.K. for five years post-merger, but U.K. politicians have been pushing hard for further commitments. While the jobs pledge is legally binding under U.K. takeover law, this may only be for a year.
The company's pledges on U.K. jobs are "unprecedented and incredible," Read argued.
Read claimed that the company did not make similar promises in the case of Swedish company Pharmacia, which has frequently been cited as an example of the U.S. giant retreating on its pledges to keep jobs. He challenged MPs to prove whether Pfizer was lying in this instance.
One of the reasons Pfizer's approach to AstraZeneca is viewed with such cynicism is because of the tax advantages to the company of such a deal. The "tax inversion" practice means that, if Pfizer spends its overseas cash on a foreign company rather than paying tax on it in the U.S., it can headquarter the merged company abroad, as long as the smaller company represents at least 20 percent of the combined company. There are concerns that, if tax is the main motivation, investment inresearch and development, and U.K. jobs, will be far down Pfizer's priority list.
Read MoreA deal to dodge the taxman
The prospect of the tax advantages of buying AstraZeneca being damaged by U.S. government intervention seem to have receded, after Orrin Hatch, a senior Republican Senator on the Senate finance committee, said "confusing and arbitrary retroactive restrictions on U.S. companies" would not solve the problem of "tax inversion."